✦ LIBER ✦

Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters

✍ Scribed by Giovanni Mantovani; Clelia Madeddu; Giulia Gramignano; Maria Rita Lusso; Miria Mocci; Elena Massa; Luca Ferreli; Giorgio Astara; Antonio Macciò; Roberto Serpe

Book ID: 114424743
Publisher: Wiley (Blackwell Publishing)
Year: 2003
Tongue: English
Weight: 188 KB
Volume: 3
Category: Article
ISSN: 1533-869X
DOI: 10.1046/j.1359-4117.2003.01096.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined maintenance treatment of cancer

Combined maintenance treatment of cancer patients responders to previous chemotherapy with immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents: clinical outcome, effects on cachexia symptoms, on proinflammatory cytokines and evaluation of quality of life

✍ G. Mantovani; A. Maccio; C. Madeddu; E. Massa; M. Mudu; C. Mulas; G. Gramignano; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 356 KB

Results of a dose-intense phase II study

Results of a dose-intense phase II study of a combination chemotherapy regimen with cisplatin (CDDP) and epirubicin (EPI) including medroxyprogesterone acetate (MPA) and recombinant interleukin 2 (rIL-2) in patients with inoperable primary lung cancer

✍ Mantovani, G; Macciò, A; Massa, E; Mudu, M.C; Manca, G; Mulas, C; Massa, D; Succ 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Preliminary results of a dose-intense ph

Preliminary results of a dose-intense phase II study of a combination chemotherapy regimen with Cisplatin (CDDP) and Epirubicin (EPI) including Medroxyprogesterone Acetate (MPA) and recombinant interleukin 2 (rIL-2) in patients with inoperable primary lung cancer

✍ Mantovani, G.; Macciò, A.; Lai, P.; Massa, E.; Mudu, M.C.; Manca, G.; Mulas, C.; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Preliminary results of a dose-intense ph

Preliminary results of a dose-intense phase II study of a combination chemotherapy regimen with cisplatin (CDDP) and epirubicin (EPI) including medroxyprogesterone acetate (MPA) and recombinant interleukin 2 (rIL-2) in patients with inoperable primary lung cancer

✍ G. Mantovani; A. Macciò; P. Lai; E. Massa; M.C. Mudu; G. Manca; C. Mulas; D. Mas 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 163 KB